Gilenya is a sphingosine 1-phosphate receptor modulator indicated and approved for the treatment of relapsing-remitting multiple sclerosis.
Gilenya causes a transient reduction in heart rate and AV conduction at treatment initiation. Potential to prolong the QT interval. Effects on immune cell numbers in the blood- decreased lymphocyte counts. Mild decrease in the neutrophil count- about 80% of original pre-therapy count. Compared to placebo, antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV, respectively. IgG titers were decreased by 45% and 50%, in response to KLH and PPV. The capacity to mount a skin delayed-type hypersensitivity reaction to Candida and tetanus toxoid was decreased by approximately 30% in subjects on gilenya 0.5 mg daily, compared to placebo. Immunologic responses were further decreased with gilenya 1.25 mg (a dose higher than recommended for MS). Single gilenya doses ≥5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance.
Bradyarrhythmia and Atrioventricular Blocks Risk of infections Macular Edema Respiratory Effects Hepatic Effects Fetal Risk Blood Pressure Effects Immune System Effects Following Gilenya Discontinuation
Strength: 0.5 Mg
Pill Imprint: FTY 0.5 Mg
Color: White & Yellow
View Images & Details